Tabrecta Unión Europea - islandés - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Dapagliflozin Viatris Unión Europea - islandés - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lyf notuð við sykursýki - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Lamictal Tuggu-/dreifitafla 50 mg Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 50 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 50 mg

Lamictal Tuggu-/dreifitafla 5 mg Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 5 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 5 mg

Lamictal Tuggu-/dreifitafla 25 mg Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 25 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 25 mg

Lamictal Tuggu-/dreifitafla 200 mg Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 200 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 200 mg

Lamictal Tuggu-/dreifitafla 2 mg Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 2 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 2 mg

Lamictal Tuggu-/dreifitafla 100 mg Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 100 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 100 mg